Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-11-21
2006-11-21
Crane, L. E. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024500, C435S006120
Reexamination Certificate
active
07138383
ABSTRACT:
Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3′-NHP(O)(S−)O-5′ linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding affinity of the parent oligonucleotide N3′→P5′ phosphoramidates and to exhibit a much higher acid stability.
REFERENCES:
patent: 4647529 (1987-03-01), Rodland et al.
patent: 5476925 (1995-12-01), Letsinger et al.
patent: 5506212 (1996-04-01), Hoke et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5591607 (1997-01-01), Gryaznov et al.
patent: 5631135 (1997-05-01), Gryaznov et al.
patent: 5645986 (1997-07-01), West et al.
patent: 5684143 (1997-11-01), Gryaznov et al.
patent: 5776679 (1998-07-01), Villeponteau et al.
patent: 5824793 (1998-10-01), Hirschbein et al.
patent: 5837857 (1998-11-01), Villeponteau et al.
patent: 5856096 (1999-01-01), Windle et al.
patent: 5958680 (1999-09-01), Villeponteau et al.
patent: 5968506 (1999-10-01), Weinrich et al.
patent: 5972605 (1999-10-01), Villeponteau et al.
patent: 6004939 (1999-12-01), Chen et al.
patent: 6015710 (2000-01-01), Shay et al.
patent: 6017895 (2000-01-01), Cook
patent: 6046307 (2000-04-01), Shay et al.
patent: 6054575 (2000-04-01), Villeponteau et al.
patent: 6258535 (2001-07-01), Villeponteau et al.
patent: 6320039 (2001-11-01), Villeponteau et al.
patent: 6342358 (2002-01-01), Collins et al.
patent: 6608036 (2003-08-01), Gryaznov et al.
patent: 6835826 (2004-12-01), Gryaznov et al.
patent: 2003/0212032 (2003-11-01), Gryaznov et al.
patent: 19720151 (1998-11-01), None
patent: 0 751 948 (2002-09-01), None
patent: 11-228451 (1998-08-01), None
patent: WO 95/25814 (1995-09-01), None
patent: WO 96/01835 (1996-01-01), None
patent: WO 97/31009 (1997-08-01), None
patent: WO 97/37891 (1997-10-01), None
patent: WO 97/38013 (1997-10-01), None
patent: WO 98/11207 (1998-03-01), None
patent: WO98/50397 (1998-11-01), None
patent: WO 98/50397 (1998-11-01), None
patent: WO 01/74136 (2001-10-01), None
R Zobkiw, L, “Studies Demonstrate Significant Anti-tumor Activity Against Human Myeloma and Lymphoma Tumors in Mice; In Vivo Data . . . ,” Press Release, Geron Corporation, Menlo Park, CA, Jun. 13, 2002, four page document.
Shea-Herbert et al., “Oligonucleotide N3′->P5′ Phosphoramidates as Efficient Telomerase Inhibitors,” Oncogene, 21, 638-642 (2002).
Glukhov et al., “Inhibition of Telomerase Activity of Melanoma Cells In Vitro by Antisense Oligonucleotides,” Biochemical and Biophysical Research Communications, 248(2), 368-371 (Jul. 20, 1998).
Pitts et al., “Inhibition of Human Telomerase by 2′-O-methyl-RNA,” Proceedings of the National Academy of Sciences USA, 95, 11549-11554 (Sep. 29, 1998).
Tao et al. (I), “Specific Inhibition of Human Telomerase Activity by Transfection Reagent, FuGENE6-Antisense Phosphorothioate Oligonucleotide Complex in HeLa Cells,” FEBS Letters, 454(3), 312-316 (Jul. 9, 1999).
Tao et al. (II), “Inhibition of Telomerase Activity . . . ,” Twentyfifth Symp. on Nucleic Acids Chemistry, Nucleic Acids Symposium Series, No. 39, pp. 85-86, Sugitomo et al. (eds.), Oxford University Press, Kobe, Japan, Sep. 18-20, 1998.
Corey DR et al, Telomerase Inhibition, Oligonucleotides, and Clinical Trials, Oncogene 21:631 (2002).
Follini M et al, Inhibition of Telomerase Activity by a Hammerhead Ribozyme Targeting the RNA Component of Telomerase in Human Melanoma Cells, J Invest Dermatol 114:259 (2000).
Gryaznov S et al, Oligonucleotide N3′→P5′ Phosphoramidates as Antisense Agents, Nucleic Acids Res 24(8):1508-1514 (1996).
Hamilton S et al, Cellular Delivery of Peptide Nucleic Acids and Inhibition of Human Telomerase, Chemistry & Biology 6:343-351 (1999).
Harrison J et al, Inhibition of Human Telomerase by PNA-Cationic Peptide Conjugates, Bioorganic & Med Chem Letters 9:1273 (1999).
Kers I et al, A New Synthetic Method for the Preparation of Nucleoside Phosphoramidate Analogues with the Nitrogen Atom in Bridging Positions of the Phosphoramidate Linkage, Tetrahedron Ltrs 39:1219-1222 (1998).
Komata T, Combination Therapy of Malignant Glioma Cells with 2-5A-Antisense Telomerase RNA and Recombinant Adenovirus p. 53, Gene Ther 7:2071 (2000).
Matthes, et al, Telomerase Protein Rather than its RNA is the Target of Phosphorothioate-Modified Oligonucleotides, Nucleic Acids Res 27:1152 (1999).
Mignet N et al, Zwitterionic Oligodeoxyribonucleotide N3′→P5′ Phosphoramidates: Synthesis and Properties, Nucleic Acids Research 26(2):431 (1998).
Muller A et al, Telomerase Inhibition by Induced Expression of Antisense RNA, Adv Exp Med Biol 451:23 (1998).
Ohnuma T et al, Inhibitory Effects of Telomere-Mimic Phosphorothioate Oligonucleotides on Various Human Tumor Cells In Vitro, Anticancer Research 17:2455-2458 (1997).
Saeki T et al, Inhibitory Effect of Telomere-Mimic Phoshporothioate Oligodeoxy Nucleotides (S-ODNS) on Human Tumor Cell Lines, Oncology 57:27 (Suppl 2) (1999).
Saretzki G et al, Ribozyme-Mediated Telomerase Inhibition Induces Immediate Cell Loss but not Telomere Shortening in Ovarian Cancer Cells, Cancer Gene Ther 8:827(2001).
Schindler A et al, Human Telomerase Reverse Transcriptase Antisense Treatment Downregulates the Viability of Prostate Cancer Cells in vitro, Int J Oncol 19:25 (2001).
Shammas M et al, Telomerase Inhibition by Peptide Nucleic Acids Teverses ‘Immortality’ of Transformed Human Cells, Oncogene 18:6191 (1999).
Tamura Y et al, Inhibition of Human Telomerse Activity by Antisense Phosphorothioate Oligonucleotides Encapsulated with the Transfection Reagent, FuGENE™6, in HeLa Cells, Antisense & Nucleic Acid Drug Dev 10:87 (2000).
Testa S et al, In Vitro Suicide Inhibition of Self-Splicing of a Group I Intron from Pneumocystis Carinil by An N3′→P5′ Phosphoramidate Hexanucleotide, Proc Natl Acad Sci USA 96:2734 (1999).
Villa R et al, Inhibition of Telomerase Activity by a Cell-Penetrating Peptide Nucleic Acid Construct in Human Melanoma Cells, FEBS Letters 473:241 (2000).
von Janta-Lipinski et al, Protein and RNA of Human Telomerase as Targets for Modified Oligonucleotides, Nucleotides & Nucleotides 18:1719 (1999).
Wagner R, Gene Inhibition Using Antisense Oligodeoxynucleotides, Nature 372:333 (1994).
Pongracz K et al, Oligonucleotide N3′.fwdarw.P5′ Thiophosphoramidates: Synthesis and Properties, Tetrahedron Ltrs 40:7661 (1999) (Oct. 22, 1999).
Zobkiw, L, “Studies Demonstrate Significant Anti-tumor Activity Against Human Myeloma and Lymphoma Tumors in Mice;In VivoData Add to Growing Evidence of Telomerase Inhibition as a Potential Treatment for Cancer,” Press Release, Geron Corporation, Menlo Park, CA, Jun. 13, 2002, four page document.
Shea-Herbert et al., “Oligonucleotide N3′>P5′ Phosphoramidates as Efficient Telomerase Inhibitors,”Oncogene, 21, 638-642 (2002).
Glukhov et al., “Inhibition of Telomerase Activity of Melanoma CellsIn Vitroby Antisense Oligonucleotides,”Biochemical and Biophysical Research Communications, 248(2), 368-371 (Jul. 20, 1998).
Pitts et al., “Inhibition of Human Telomerase by 2′-O-methyl-RNA,”Proceedings of the National Academy of Sciences USA, 95, 11549-11554 (Sep. 29, 1998).
Tao et al. (I), “Specific Inhibition of Human Telomerase Activity by Transfection Reagent, FuGENE6-Antisense Phosphorothioate Oligonucleotide Complex in HeLa Cells,”FEBS Letters, 454(3), 312-316 (Jul. 9, 1999).
Tao et al. (II), “Inhibition of Telomerase Activity by Antisense Oligonucleotides in HeLa Cells,”Twentyfifth Symp. on Nucleic Acids Chemistry, Nucleic Acids Symposium Series, No. 39, pp. 85-86, Sugitomo et al. (eds.), Oxford University Press, Kobe, Japan, Sep. 18-20, 1998.
Gryaznov Sergei
Matray Tracy
Pongracz Krisztina
Crane L. E.
Earp David J.
Geron Corporation
LandOfFree
Treating cancer using an oligonucleotide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating cancer using an oligonucleotide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating cancer using an oligonucleotide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3635796